How Much of a Cancer Drug Is Too Much? Patients, Researchers Challenge FDA-Approved ...

Patients and researchers are challenging FDA-approved dosages of expensive immunotherapy cancer drugs like nivolumab (Opdivo) and pembrolizumab (Keytruda), advocating for studies to optimise dosing to reduce side effects and costs. Evidence shows lower doses can be effective and could save billions in healthcare costs, but pharma companies resist dose reductions as they impact profits.

This Wire brief sits within Fusion42's coverage of Health.